Mohammed Qatanani
Directeur Technique/Scientifique/R&D chez SCHOLAR ROCK HOLDING CORPORATION
Fortune : 1 M $ au 31/05/2024
Postes actifs de Mohammed Qatanani
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Directeur Technique/Scientifique/R&D | 01/09/2022 | - |
Historique de carrière de Mohammed Qatanani
Anciens postes connus de Mohammed Qatanani
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/02/2018 | 01/09/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2015 | 01/01/2018 |
Formation de Mohammed Qatanani
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
| Liban | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Mohammed Qatanani
- Expérience
